Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies | MicrobiomeTrials← Back to trialsNCT05327023
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2022-05-23Est. Completion: 2028-07-03
Enrollment target: 430 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Relapsed Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaB-cell Acute Lymphoblastic LeukemiaPediatric CancerPediatric ALL, RelapsedPediatric ALLPediatric ALL, B CellAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaPediatric AMLR/R AMLR/R B-cell ALL
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescen…
Multiple LocationsEst. completion Apr 30, 2030
Phase 3
Recruiting
Intrahepatic Cholangiocarcinoma (Icc)
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety o…
Guangzhou, ChinaEst. completion Jan 2030
DOCK8 Deficiency
Background:
-DOCK8 deficiency is a genetic disorder that affects the immune system and can lead to severe recurrent inf…
Bethesda, United StatesEst. completion Oct 31, 2026